Affimed N.V. (NASDAQ:AFMD) reports 1Q18 Loss Confined; Beats Street View

Affimed N.V.

Affimed N.V. (NASDAQ:AFMD) reported net loss for the first quarter of $ 8.2 million or $ 0.15 per share, compared to loss $ 7.76 million or $ 0.19 per share for the year-ago quarter.

The Heidelberg, Germany based company recorded revenue for first quarter rose 33% to $ 0.53 million from $ 0.40 million in the same quarter last year.

Analysts polled by Thomson Reuters expected AFMD to report loss of $ 0.18 per share on revenue of $ 0.47 million for the first quarter.

The ability to utilize different antibody formats to activate innate and adaptive immune cells is in our minds a prerequisite to developing effective therapies for different cancers and other life-threatening diseases, said Dr. Adi Hoess, Affimed’s CEO.

Be the first to comment

Leave a Reply

Your email address will not be published.


*